<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03494504</url>
  </required_header>
  <id_info>
    <org_study_id>ADX-102-AC-008</org_study_id>
    <nct_id>NCT03494504</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study of Reproxalap in Subjects With Allergic Conjunctivitis</brief_title>
  <official_title>A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions (0.25% and 0.5%) Compared to Vehicle in the Conjunctival Allergen Challenge (Ora-CACÂ®) Model of Acute Allergic Conjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aldeyra Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aldeyra Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Clinical Trial
      to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions in Subjects with Acute
      Allergic Conjunctivitis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular itching evaluated by the Subject.</measure>
    <time_frame>Efficacy assessment period (Day -21 through Day 1)</time_frame>
    <description>The method of assessment for this outcome is the Ora Calibra(TM) Conjunctival Allergen Challenge Ocular Itching Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conjunctival redness</measure>
    <time_frame>Efficacy assessment period (Day -21 through Day 1)</time_frame>
    <description>The method of assessment for this outcome is the Ora Calibra(TM) Ocular Hyperemia Scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Reproxalap Ophthalmic Solution (0.25%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Reproxalap Ophthalmic Solution (0.5%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Ophthalmic Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reproxalap Ophthalmic Solution (0.25%)</intervention_name>
    <description>Reproxalap Ophthalmic Solution (0.25%) administered once.</description>
    <arm_group_label>Reproxalap Ophthalmic Solution (0.25%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reproxalap Ophthalmic Solution (0.5%)</intervention_name>
    <description>Reproxalap Ophthalmic Solution (0.5%) administered once.</description>
    <arm_group_label>Reproxalap Ophthalmic Solution (0.5%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Ophthalmic Solution</intervention_name>
    <description>Vehicle Ophthalmic Solution administered once.</description>
    <arm_group_label>Vehicle Ophthalmic Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  be at least 18 years of age of either gender and any race

          -  have a positive history of ocular allergies and a positive skin test reaction to a
             seasonal allergen (grasses, ragweed, and/or trees) as confirmed by an allergic skin
             test at the Screening Visit or within the past 24 months;

          -  have a calculated visual acuity of 0.7 logMAR or better in each eye as measured using
             an ETDRS chart

        Exclusion Criteria:

          -  have known contraindications or sensitivities to the use of the investigational
             product or any of its components

          -  have any ocular condition that, in the opinion of the investigator, could affect the
             subject's safety or trial parameters (including but not limited to narrow angle
             glaucoma, clinically significant blepharitis, follicular conjunctivitis, iritis,
             pterygium or a diagnosis of dry eye)

          -  have had ocular surgical intervention within three (3) months prior to Visit 1 or
             during the trial and/or a history of refractive surgery six (6) months prior to Visit
             1 or have ocular or systemic surgery planned during the study or within 30 days after

          -  have a known history of retinal detachment, diabetic retinopathy, or active retinal
             disease

          -  have the presence of an active ocular infection (bacterial, viral or fungal) or
             positive history of an ocular herpetic infection at any visit

          -  be a female who is currently pregnant, planning a pregnancy, lactating, not using a
             medically acceptable form of birth control throughout the trial duration, or has a
             positive urine pregnancy test at Visit 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jack V. Greiner, DO</last_name>
      <phone>617-248-3875</phone>
      <email>charlesrivereye@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2018</study_first_submitted>
  <study_first_submitted_qc>April 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2018</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

